Razi Khan1, Eric Rheaume2, Jean-Claude Tardif2. 1. Royal Columbian Hospital, 330 E Columbia St., New Westminster, BC, V3L 3W7, Canada. razi.khan@gmail.com. 2. Montreal Heart Institute, Montreal, QC, H1T 1C8, Canada.
Abstract
PURPOSE: The purpose of this review was to examine the role of IL-1β in the inflammatory process central to the development of atherosclerosis and to discuss current clinical evidence for treatments targeting IL-1β in coronary artery disease. RECENT FINDINGS: IL-1β has been shown to modulate atherosclerotic plaque progression by upregulating the synthesis of adhesion molecules on endothelial cells, as well increasing activation and proliferation of vascular smooth muscle cells. Animal studies have further suggested that alterations in the balance between agonists and antagonists of IL-1β are important in promoting atherosclerosis. In humans, preliminary assessment of therapy targeting IL-1β noted early reductions in serum inflammatory biomarkers among those with systemic inflammatory or coronary artery disease. The CANTOS trial, a large randomized double-blind study found that canakinumab, a monoclonal antibody targeting IL-1β, reduced ischemic events in patients being treated for secondary prevention. Cellular, animal, and now clinical studies have suggested a role for therapies aimed at IL-1β for treatment of CAD. However, given potential side effects and costs of these medications, further study is required to determine which patients may be most suited for treatment above current standard of care.
PURPOSE: The purpose of this review was to examine the role of IL-1β in the inflammatory process central to the development of atherosclerosis and to discuss current clinical evidence for treatments targeting IL-1β in coronary artery disease. RECENT FINDINGS: IL-1β has been shown to modulate atherosclerotic plaque progression by upregulating the synthesis of adhesion molecules on endothelial cells, as well increasing activation and proliferation of vascular smooth muscle cells. Animal studies have further suggested that alterations in the balance between agonists and antagonists of IL-1β are important in promoting atherosclerosis. In humans, preliminary assessment of therapy targeting IL-1β noted early reductions in serum inflammatory biomarkers among those with systemic inflammatory or coronary artery disease. The CANTOS trial, a large randomized double-blind study found that canakinumab, a monoclonal antibody targeting IL-1β, reduced ischemic events in patients being treated for secondary prevention. Cellular, animal, and now clinical studies have suggested a role for therapies aimed at IL-1β for treatment of CAD. However, given potential side effects and costs of these medications, further study is required to determine which patients may be most suited for treatment above current standard of care.
Authors: E V Granowitz; A A Santos; D D Poutsiaka; J G Cannon; D W Wilmore; S M Wolff; C A Dinarello Journal: Lancet Date: 1991-12-07 Impact factor: 79.321
Authors: Antonio Abbate; Michael Christopher Kontos; Nayef Antar Abouzaki; Ryan David Melchior; Christopher Thomas; Benjamin Wallace Van Tassell; Claudia Oddi; Salvatore Carbone; Cory Ross Trankle; Charlotte Susan Roberts; George Herman Mueller; Michael Lucas Gambill; Sanah Christopher; Roshanak Markley; George Wayne Vetrovec; Charles Anthony Dinarello; Giuseppe Biondi-Zoccai Journal: Am J Cardiol Date: 2014-11-13 Impact factor: 2.778